ArticleCureus2025
Spontaneous Hepatic Hemorrhage as a Rare Presentation of Amyloid Light Chain (AL) Amyloidosis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spontaneous hepatic hemorrhage due to amyloidosis light chain (AL) is a rare but serious life-threatening condition. In this case, a 64-year-old male patient presented to the emergency room with acute right shoulder pain. He was recently diagnosed with type 2 diabetes. He did not have any recent trauma, procedures, history of hepatitis, alcoholism, or chronic inflammatory or bleeding disorders. The patient's computed tomography (CT) scan of the abdomen was positive for acute subcapular hematoma. He developed acute nephrotic syndrome within two days of admission. Further workup showed elevated monoclonal lambda light chains and confirmed AL amyloidosis on bone marrow biopsy. This case is unique because subcapsular hepatic hematoma was the only manifestation of AL amyloidosis. While amyloid deposition does occur in systemic amyloidosis, it is exceptionally rare for patients to present with spontaneous hepatic rupture without any prior diagnosis. Recognizing this atypical presentation of AL amyloidosis is crucial for timely intervention and improved outcomes. Familiarity with the rare etiology of intrahepatic hemorrhage may help to decrease the high mortality rate associated with this rare disease. Treatment for hepatic hemorrhage consists of aggressive blood transfusion and CT-guided hepatic artery embolization. Chemotherapy with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) can halt amyloid deposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.